Bromoscan-Competitive Ligand Binding Assay

Eurofins Discovery offers a suite of assays for epigenetic targets to enable identification and classification of inhibitors based on potency, selectivity and in vitro efficacy. BROMOscan^™, is an industry leading collection of 36 validated, quantitative binding assays. Used alone or in combination, this powerful platform can be applied to all stages of drug discovery and are ideal for identifying potent and selective small molecule inhibitors to emerging epigenetic targets.